Shopping Cart
- Remove All
- Your shopping cart is currently empty
Capmatinib 2HCl.H2O (NVP-INC280 2HCl.H2O) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
2 mg | $30 | In Stock | |
5 mg | $45 | In Stock | |
10 mg | $63 | In Stock | |
25 mg | $117 | In Stock | |
50 mg | $186 | In Stock | |
100 mg | $297 | In Stock | |
200 mg | $397 | In Stock | |
1 mL x 10 mM (in DMSO) | $51 | In Stock |
Description | Capmatinib 2HCl.H2O (NVP-INC280 2HCl.H2O) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity. |
In vitro | Capmatinib was found to be highly selective for MET over other kinases.?It was active against cancer models that are characterized by MET amplification, marked MET overexpression, MET exon 14 skipping mutations, or MET activation via expression of the ligand hepatocyte growth factor (HGF)[1]. |
In vivo | In cancer models where MET is the dominant oncogenic driver, anticancer activity could be further enhanced by combination treatments, for example, by the addition of apoptosis-inducing BH3 mimetics.?The combinations of capmatinib and other kinase inhibitors resulted in enhanced anticancer activity against models where MET activation co-occurred with other oncogenic drivers, for example EGFR activating mutations[1]. |
Alias | NVP-INC280 2HCl.H2O, INCB28060 2HCl.H2O, INC-280 2HCl.H2O |
Molecular Weight | 503.36 |
Formula | C23H21Cl2FN6O2 |
Cas No. | 1865733-40-9 |
Smiles | O=C(C1=C(F)C=C(C2=NN3C(N=C2)=NC=C3CC4=CC=C5N=CC=CC5=C4)C=C1)NC.Cl.O.Cl |
Relative Density. | no data available |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
Solubility Information | DMSO: 30 mg/mL (59.6 mM), Sonication is recommended. ![]() | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.